Allied finds CardioCel better at seeding stem cells

Tests of tissue engineered by Allied Healthcare’s (ASX:AHZ) ADAPT technology support its ability to be used for a “truly regenerative treatment”, according to its CEO.

Allied Healthcare (ASX:AHZ) said the results of a joint study with the CSIRO show its CardioCel tissue patch is superior at stem cell seeding than gold-standard alternatives in surgical use.

The preclinical study evaluated the ability of CardioCel tissue, produced using the company’s ADAPT tissue engineering technology, to maintain a population of mesencymal stem cells (MSCs).

CardioCel tissue was measured against the MPC-maintaining ability of the glutaraldehyde-prepared tissue widely used in current cardiac repair surgeries.

Allied Healthcare said the results show that CardioCel engineered tissue demonstrated significantly better stem cell viability at one day post-seeding and high cell viability at day seven. By comparison, by the seventh day, virtually no MSCs had survived on the control tissue.

Allied Healthcare CEO Lee Rodne said the in situ data suggests that CardioCel tissue could support seeding by endogenous stem cells.

“[This] broadens the potential of ADAPT prepared tissue to be used as scaffolds to seed and deliver stem cells for soft tissue repair, [which] expands the potential of our ADAPT tissue to be used as a truly regenerative treatment for a number of diseases and conditions,” he said.

Rodne added that the data also supports the company’s preclinical research into using CardioCel patches in heart valve reconstruction.

CardioCel was used for the first time outside of clinical trials in October last year, during a procedure at the Mater Hospital in Brisbane.

Allied Healthcare is also exploring using its ADAPT technology to develop products aimed at applications including hernia repair and pelvic floor reconstruction, as well as orthopaedics.

After climbing 13% yesterday, Allied Healthcare (ASX:AHZ) shares were trading 7.69% higher at $0.028 as of 2:30 pm on Wednesday.